2nd Covalent Drug Discovery and Development Summit

Kongressthemen
Uniting Large Pharma, Innovative Biotech and Leading Academics to Eliminate the Boundaries of Druggability with Novel Covalent Drugs

With continued advancements in screening platforms and proteomics, the covalency renaissance continues as biopharma race to unlock hard-to-target proteins across oncology, immunology and CNS. We are witnessing this industry make great strides in utilizing novel covalent modalities and elucidating novel warheads to target amino acids beyond cysteine.

Kongressorganizer (PCO)
Hanson Wade

Anmerkungen
URL:
Brochure: https://go.evvnt.com/2537785-3?pid=4832

Speakers: Adam Cotton -Associate - Novartis Venture Fund, Andrea Zuhl -Vice President, Chemical Biology and Proteomics - HYKU Biosciences, and more

https://go.evvnt.com/2537785-2?pid=4832

Frau Rosie Andre